A federal court ruling on the legality and constitutionality of Arkansas’s 340B nondiscrimination law might not come until sometime in 2023.
U.S. Senior District Judge Billy Roy Wilson on Monday issued an initial scheduling order in the drug industry lawsuit
…
UPDATE Tuesday, Oct. 26, 2021, 5:00 p.m. EDT—We have updated this article to reflect new information from the California Department of Health Care Services (DHCS) about the timeframe for the U.S. Centers for Medicare & Medicaid Services (CMS) to complete
…
The Arkansas Insurance Department (AID) is ending the drug industry’s state administrative proceeding to stop the department from implementing and enforcing the state’s novel 340B contract pharmacy law.
In his Oct. 5 order ending the proceeding, Insurance Commissioner Alan
…
An Arkansas Insurance Department hearing officer said last week she would decide by Oct. 13 whether to stay enforcement of a state law requiring drug manufacturers to honor 340B contract pharmacy arrangements pending resolution of a bevy of federal lawsuits
…
North Carolina lawmakers approved a final deal Wednesday to protect some, but not all, of the state’s 340B covered entities against discrimination by pharmacy benefit managers (PBMs).
Under an agreement a House-Senate conference committee reached on Sept. 8, 340B
…
The Arkansas Insurance Department is holding a public hearing this Friday morning on whether it should strike down as unconstitutional the nation’s first state law to address pharmaceutical manufacturer denials of 340B pricing on drugs when they are dispensed by
…
North Carolina lawmakers are debating whether to grant all 340B covered entities and their contract pharmacies, or only some, protection against discrimination by pharmacy benefit managers.
Last week Thursday, state House and Senate leaders appointed members to a conference committee
…
340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.
…
California’s twice-postponed shift of Medicaid (Medi-Cal) managed care prescription drug benefits to Medi-Cal fee for service (FFS) is back on for Jan. 1, 2022, one year later than originally planned.
A similar high-stakes battle over Medicaid reimbursement for 340B-purchased drugs
…*Sign up for news summaries and alerts from 340B Report